Tumor-associated antigens on autologous cervical cancer cells (TAA)

Tumor-associated antigens (TAAs) on autologous cervical cancer cells represent a heterogeneous collection of proteins that are uniquely presented by a patient's own tumor tissue. In cervical cancer, these antigens prominently include oncoproteins derived from Human Papillomavirus (HPV), specifically E6 and E7, which are critical for the maintenance of the malignant phenotype (Frontiers in Immunology, 2020). Beyond viral proteins, the target repertoire includes neoantigens arising from somatic mutations and overexpressed self-proteins that the immune system can recognize as foreign. These antigens serve as the primary targets for adoptive cell therapies, such as tumor-infiltrating lymphocytes (TILs), which are harvested from the patient, expanded ex vivo, and re-infused to mount a polyvalent immune attack (Journal of Clinical Investigation, 2007). Drugs like lifileucel (LN-145) utilize this approach to treat advanced or metastatic cervical cancer by leveraging the natural ability of T-cells to recognize the full breadth of a patient's autologous antigenic profile (Iovance Biotherapeutics, 2024). This strategy is particularly effective in overcoming tumor heterogeneity and providing a personalized therapeutic response in patients who have failed standard chemotherapy.

Other names

Autologous tumor antigensCervical cancer tumor-associated antigensTumor-infiltrating lymphocyte targetsAutologous cervical cancer cell antigens

Adoptive cell transfer involving the recognition of multiple tumor-specific and tumor-associated antigens by ex vivo expanded autologous tumor-infiltrating lymphocytes, leading to MHC-restricted tumor cell lysis.